ロード中...
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
SIMPLE SUMMARY: Thymic carcinoma is a rare neoplasm with a poor outcome, and there are no established therapeutic regimens for metastatic or recurrent disease. Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies, are approved in several human cancers, however, ICIs are not approved in...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7959131/ https://ncbi.nlm.nih.gov/pubmed/33802298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051065 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|